ACM
NRIX icon

Aster Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Aster Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-275
Closed -$3.27K – 1129
2026
Q1 		$3.27K Buy
275
+271
+6,775% +$4.49K ﹤0.01% 720
2025
Q4 		$76 Buy
+4
New +$57 ﹤0.01% 1045
2025
Q2 		– Sell
-833
Closed -$12.9K – 1403
2025
Q1 		$12.9K Buy
833
+595
+250% +$9.95K ﹤0.01% 1037
2024
Q4 		$4.48K Buy
+238
New +$5.46K ﹤0.01% 872

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aster Capital Management's NRIX Position: Q2 2026 in Review

Aster Capital Management sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 275 shares — an estimated $3.27K sold.

Aster Capital Management first reported a position in NRIX in Q4 2024 and held it in 4 quarters. The position peaked at $12.9K in Q1 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Aster Capital Management reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aster Capital Management sold 275 Nurix Therapeutics shares in Q2 2026, an estimated $3.27K.
  • Aster Capital Management first reported a position in Nurix Therapeutics in Q4 2024 and held it in 4 quarters.
  • Aster Capital Management's Nurix Therapeutics position peaked at $12.9K in Q1 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.